Literature DB >> 7888679

Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.

M Zhou1, A M Yeager, S D Smith, H W Findley.   

Abstract

The wild-type (wt) p53 tumor suppressor gene is commonly inactivated in human malignancies, either by mutations or by loss of expression. An additional proposed mechanism for inactivation of wt-p53 is amplification of the murine double minute 2 (MDM2) gene and overexpression of the MDM2 protein, which binds to p53 and eliminates its tumor suppressor function. To investigate a potential role for MDM2 in the inactivation of wt-p53 in pediatric acute lymphoblastic leukemia (ALL), we examined the expression of MDM2 and p53, as well as the occurrence of p53 mutations and possible amplification of the MDM2 gene, in 19 pediatric ALL cell lines and one pediatric acute myelogenous leukemia (AML) line. Although we did not find significant amplification of the MDM2 gene in any of the leukemic lines, we detected overexpression of MDM2 in all 10 lines that expressed wt-p53. Of the 10 lines without overexpression of the MDM2 gene, six (including the AML line) did not express p53, and four expressed mutant p53 with single point mutations in exons 7 and 8. To determine whether primary leukemic cells showed a similar correlation, we analyzed the original cryopreserved leukemic bone marrow cells from seven patients from whom cell lines were established. We obtained similar results from both the primary leukemic cells and the corresponding cell lines: overexpression of MDM2 was present in primary cells that expressed wt-p53 but not in cells that lacked expression of wt-p53. These findings suggest an important role for MDM2 in the pathogenesis of pediatric ALL in which leukemic cells express wt-p53.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7888679

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

Authors:  Shunbin Xiong; Vinod Pant; Young-Ah Suh; Carolyn S Van Pelt; Yongxing Wang; Yasmine A Valentin-Vega; Sean M Post; Guillermina Lozano
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

2.  MDMX: a novel p53-binding protein with some functional properties of MDM2.

Authors:  A Shvarts; W T Steegenga; N Riteco; T van Laar; P Dekker; M Bazuine; R C van Ham; W van der Houven van Oordt; G Hateboer; A J van der Eb; A G Jochemsen
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

3.  Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway.

Authors:  Mei Huang; Hailong Zhang; Tao Liu; Dan Tian; Lubing Gu; Muxiang Zhou
Journal:  Mol Cancer Ther       Date:  2012-12-12       Impact factor: 6.261

4.  Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.

Authors:  C Xu; C D Fan; X Wang
Journal:  Oncogene       Date:  2014-01-13       Impact factor: 9.867

5.  Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.

Authors:  Kailiang Zhao; Yang Yang; Guang Zhang; Chenfeng Wang; Decai Wang; Mian Wu; Yide Mei
Journal:  EMBO Rep       Date:  2018-01-02       Impact factor: 8.807

6.  Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Alexander Draganov; Sha Yi; Binghe Wang; Muxiang Zhou
Journal:  Mol Cancer Ther       Date:  2017-12-27       Impact factor: 6.261

7.  Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells.

Authors:  Xiaoling Zhang; Lubing Gu; Jiansha Li; Noopur Shah; Jing He; Lin Yang; Qun Hu; Muxiang Zhou
Journal:  Cancer Res       Date:  2010-10-08       Impact factor: 12.701

8.  Methylation of RASSF1A gene promoter is regulated by p53 and DAXX.

Authors:  Hailong Zhang; Jing He; Jiansha Li; Dan Tian; Lubing Gu; Muxiang Zhou
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

9.  Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Sheng Zhou; Yuhong Du; Jing Xiong; Sha Yi; Cheng-Kui Qu; Haian Fu; Muxiang Zhou
Journal:  Cancer Cell       Date:  2016-09-22       Impact factor: 31.743

10.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

Authors:  L Gu; N Zhu; H W Findley; M Zhou
Journal:  Leukemia       Date:  2008-02-14       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.